
    
      The primary objective of this study is to describe the level of serum antibody and cellular
      immune responses conferred by FluMist and TIV against antigenically matched and antigenically
      mismatched influenza virus strains.

      The secondary objective of this study is to describe the safety of FluMist and TIV in
      subjects 12 to <36 months of age.
    
  